Santos Luis E, Mattos Paulo, Pinheiro Thais L, Silva Ananssa, Drummond Claudia, Sudo Felipe Kenji, Barros-Aragão Fernanda, Vanderborght Bart, Brandão Carlos Otávio, Ferreira Sergio T, Tovar-Moll Fernanda, De Felice Fernanda G
D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.
Program in Morphological Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Nat Commun. 2025 Mar 25;16(1):2911. doi: 10.1038/s41467-025-56756-3.
Despite remarkable progress in the biomarker field in recent years, local validation of plasma biomarkers of Alzheimer's disease (AD) and dementia is still lacking in Latin America. In this longitudinal cohort study of 145 elderly Brazilians, we assess the diagnostic performance of plasma biomarkers, based on clinical diagnosis and CSF biomarker positivity. Follow-up data of up to 4.7 years were used to determine performance in predicting diagnostic conversions. Participants were clinically categorized as cognitively unimpaired (n = 49), amnestic mild cognitive impairment (n = 29), AD (n = 38), Lewy body dementia (n = 22), or vascular dementia (n = 7). Plasma Tau, Aβ, Aβ, NfL, GFAP, pTau231, pTau181 and pTau217 were measured on the SIMOA HD-X platform. Plasma pTau217 showed excellent performance determining CSF biomarker status in the cohort, either alone (ROC AUC = 0.94, 95% CI: [0.88-1.00]) or as a ratio to Aβ (ROC AUC = 0.98, 95% CI: [0.94-1.00]). This study comprises an initial step towards local validation and adoption of dementia biomarkers in Brazil.
尽管近年来生物标志物领域取得了显著进展，但拉丁美洲仍缺乏对阿尔茨海默病（AD）和痴呆症血浆生物标志物的本地验证。在这项对145名巴西老年人进行的纵向队列研究中，我们基于临床诊断和脑脊液生物标志物阳性情况评估了血浆生物标志物的诊断性能。使用长达4.7年的随访数据来确定预测诊断转换的性能。参与者在临床上被分类为认知未受损（n = 49）、遗忘型轻度认知障碍（n = 29）、AD（n = 38）、路易体痴呆（n = 22）或血管性痴呆（n = 7）。在SIMOA HD-X平台上测量血浆Tau、Aβ、Aβ、NfL、GFAP、pTau231、pTau181和pTau217。血浆pTau217在该队列中单独（ROC曲线下面积 = 0.94，95%置信区间：[0.88 - 1.00]）或以与Aβ的比率（ROC曲线下面积 = 0.98，95%置信区间：[0.94 - 1.00]）来确定脑脊液生物标志物状态时表现出优异性能。这项研究是巴西朝着本地验证和采用痴呆症生物标志物迈出的第一步。
